Cargando…

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma

Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao, Wang, Dongdong, Wang, Guangfei, Huang, Yidie, Yu, Xin, Lu, Jinmiao, Zhai, Xiaowen, Xu, Hong, Li, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606893/
https://www.ncbi.nlm.nih.gov/pubmed/34819851
http://dx.doi.org/10.3389/fphar.2021.668952
_version_ 1784602435520561152
author Chen, Xiao
Wang, Dongdong
Wang, Guangfei
Huang, Yidie
Yu, Xin
Lu, Jinmiao
Zhai, Xiaowen
Xu, Hong
Li, Zhiping
author_facet Chen, Xiao
Wang, Dongdong
Wang, Guangfei
Huang, Yidie
Yu, Xin
Lu, Jinmiao
Zhai, Xiaowen
Xu, Hong
Li, Zhiping
author_sort Chen, Xiao
collection PubMed
description Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future.
format Online
Article
Text
id pubmed-8606893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86068932021-11-23 Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma Chen, Xiao Wang, Dongdong Wang, Guangfei Huang, Yidie Yu, Xin Lu, Jinmiao Zhai, Xiaowen Xu, Hong Li, Zhiping Front Pharmacol Pharmacology Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606893/ /pubmed/34819851 http://dx.doi.org/10.3389/fphar.2021.668952 Text en Copyright © 2021 Chen, Wang, Wang, Huang, Yu, Lu, Zhai, Xu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Xiao
Wang, Dongdong
Wang, Guangfei
Huang, Yidie
Yu, Xin
Lu, Jinmiao
Zhai, Xiaowen
Xu, Hong
Li, Zhiping
Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_full Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_fullStr Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_full_unstemmed Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_short Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_sort optimization of initial dose regimen for sirolimus in pediatric patients with lymphangioma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606893/
https://www.ncbi.nlm.nih.gov/pubmed/34819851
http://dx.doi.org/10.3389/fphar.2021.668952
work_keys_str_mv AT chenxiao optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT wangdongdong optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT wangguangfei optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT huangyidie optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT yuxin optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT lujinmiao optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT zhaixiaowen optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT xuhong optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
AT lizhiping optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma